Key result
Dexmedetomidine cuts postoperative AKI ~40% versus controls in cardiac surgery.
Why the study?
Does perioperative dexmedetomidine reduce the incidence of postoperative acute kidney injury in adult patients undergoing cardiac surgery?
Meta-Analysis (n=1,308)
Does perioperative dexmedetomidine reduce the incidence of postoperative acute kidney injury in adult patients undergoing cardiac surgery?
Effect estimate: RR 0.60 (95% CI 0.41-0.87)
Absolute Event Rate: 10.9% vs 18.3%
p-value: p=0.008
Perioperative dexmedetomidine administration significantly reduces the risk of acute kidney injury in adult patients undergoing cardiac surgery, particularly when initiated before or during surgery.
No takes yet. Share an insight, caveat, or question.
Supports perioperative dexmedetomidine for AKI prevention in cardiac surgery; strengthens low-certainty evidence from 11 trials.
Peng et al. (2019) conducted a meta-analysis in Cardiac surgery-associated acute kidney injury (n=1,308). Dexmedetomidine vs. Control group (saline or other sedatives) was evaluated on Incidence of postoperative acute kidney injury (CS-AKI) (RR 0.60, 95% CI 0.41-0.87, p=0.008). Dexmedetomidine reduced the incidence of postoperative acute kidney injury by 40% compared to controls in adult patients undergoing cardiac surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: